Silo Pharma, Inc.

Name: Silo Pharma, Inc. standardized financial statements, quarterly
Creator: Listed

SILONasdaqCIK 1514183HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$0, Q2 FY2026

Operating income−$928.9k, Q2 FY2026

Net income−$832.8k, Q2 FY2026

Silo Pharma, Inc., income statement, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Revenue	$k	18.0	18.0	18.0	18.0	18.0	18.0	18.0	18.0	18.0	18.0	18.0	0.0
Cost of revenue	$k	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	20.7	20.7	20.7	0.0
Gross profit	$k	16.6	16.6	16.6	16.6	16.6	16.6	16.6	16.6	(2.7)	(2.7)	(2.7)	0.0
Research and development	$k	174	337	318	393	518	1,076	594	717	544	306	1,013	298
Selling, general and administrative	$k	not reported	not reported	64.4	50.6	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Operating income	$k	(773)	(1,164)	(880)	(1,003)	(1,010)	(1,813)	(1,094)	(1,249)	(1,151)	(787)	(1,595)	(929)
Interest expense	$k	1.1	0.3	1.9	1.9	1.1	0.3	2.1	1.6	0.9	32.7	3.4	2.9
Income tax	$k	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Net income	$k	(660)	(1,121)	(802)	(932)	(929)	(1,731)	(1,031)	(1,204)	(1,110)	(882)	(1,647)	(833)
Diluted EPS	$ per share	(0.21)	not reported	(0.28)	(0.31)	(0.22)	not reported	(0.23)	(2.88)	(0.12)	not reported	(0.12)	(0.76)
Basic EPS	$ per share	(0.21)	not reported	(0.28)	(0.31)	(0.22)	not reported	(0.23)	(2.88)	(0.12)	not reported	(0.12)	(0.76)

Balance sheet

Cash and equivalents$3.3m, Q2 FY2026

Shareholders' equity$4.9m, Q2 FY2026

Silo Pharma, Inc., balance sheet, quarterly
Line item	Unit	FY20232023-12-31	Q1 FY20242024-03-31	period not labelled2024-06-04	Q2 FY20242024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$k	3,524	2,668	0.0	4,506	4,861	3,906	3,137	4,334	3,918	4,749	3,903	3,277
Current assets	$k	7,681	6,878	not reported	7,729	8,262	7,111	5,604	6,373	6,164	7,388	6,804	5,714
Total assets	$k	7,746	6,941	not reported	8,038	8,567	7,412	5,900	6,653	6,385	7,605	7,018	5,952
Current liabilities	$k	776	874	not reported	1,323	1,045	1,656	1,185	1,050	708	650	705	1,066
Total liabilities	$k	1,569	1,649	not reported	2,081	1,784	2,378	1,889	1,735	1,376	1,300	1,336	1,066
Shareholders' equity	$k	6,177	5,292	not reported	5,958	6,782	5,034	4,011	4,917	5,009	6,305	5,682	4,886

Cash flow

Operating cash flow−$781.9k, Q2 FY2026

Silo Pharma, Inc., cash flow, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$k	(1,072)	(910)	(838)	(732)	(1,347)	(917)	(1,640)	(1,285)	(955)	(780)	(823)	(782)

Diluted shares (weighted)1.10m, Q2 FY2026

Silo Pharma, Inc., shares, quarterly
Line item	Unit	Q3 FY20222022-09-30	Q1 FY20232023-03-31	Q2 FY20232023-06-30	Q3 FY20232023-09-30	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Diluted shares (weighted)	m shares	2.0	3.2	3.2	3.1	2.9	3.1	4.3	4.5	0.4	9.3	13.7	1.1

Shares outstanding: 1.59m at Aug 13, 2026, from the cover of the 10-Q filed Aug 13, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:41 ET. Listed shows no prices and gives no investment advice.